Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,

Double Blind ◽

Safety And Efficacy ◽

Efficacy Analysis ◽

Castration Resistant ◽

Endothelin A Receptor ◽

Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4664 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4664-4664 ◽

Cited By ~ 3

Author(s):

D. L. Trump ◽

H. Payne ◽

K. Miller ◽

J. S. De Bono ◽

J. Stephenson ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Receptor Antagonist ◽

Phase I Study ◽

Castration Resistant ◽

Endothelin A Receptor ◽

7013 Phase II trial of the specific endothelin A receptor antagonist zibotentan (ZD4054) in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases: final analysis of safety and efficacy

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71391-6 ◽

2009 ◽

Vol 7 (2) ◽

pp. 410 ◽

Cited By ~ 2

Author(s):

N.D. James ◽

T. Morris ◽

D. Phung ◽

S. McIntosh ◽

N.A. Dawson

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Receptor Antagonist ◽

Phase Ii ◽

Phase Ii Trial ◽

Final Analysis ◽

Safety And Efficacy ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Resistant Prostate Cancer

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer

The Prostate ◽

10.1002/pros.21342 ◽

2011 ◽

Vol 71 (12) ◽

pp. 1264-1275 ◽

Cited By ~ 7

Author(s):

Donald L. Trump ◽

Heather Payne ◽

Kurt Miller ◽

Johann S. de Bono ◽

Joe Stephenson ◽

...

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Castration Resistant ◽

Endothelin A Receptor ◽

Preliminary Study ◽

ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer

Expert Opinion on Investigational Drugs ◽

10.1517/13543784.17.8.1237 ◽

2008 ◽

Vol 17 (8) ◽

pp. 1237-1245 ◽

Cited By ~ 27

Author(s):

Ruth Warren ◽

Glenn Liu

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Castration Resistant ◽

Endothelin A Receptor ◽

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

European Urology ◽

10.1016/j.eururo.2008.11.002 ◽

2009 ◽

Vol 55 (5) ◽

pp. 1112-1123 ◽

Cited By ~ 119

Author(s):

Nicholas D. James ◽

Armelle Caty ◽

Michael Borre ◽

Bernard A. Zonnenberg ◽

Philippe Beuzeboc ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Phase 2 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Phase 2 Trial ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Resistant Prostate Cancer

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer

PLoS ONE ◽

10.1371/journal.pone.0133803 ◽

2015 ◽

Vol 10 (7) ◽

pp. e0133803 ◽

Cited By ~ 4

Author(s):

Ping Qi ◽

Ming Chen ◽

Li-xiu Zhang ◽

Rui-xia Song ◽

Zhen-hua He ◽

...

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Meta Analysis ◽

Indirect Comparison ◽

Castration Resistant ◽

Endothelin A Receptor ◽

Faculty Opinions recommendation of Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.9875966.793494170 ◽

2014 ◽

Author(s):

Thomas Flaig

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Castration Resistant

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70474-7 ◽

2014 ◽

Vol 15 (12) ◽

pp. 1397-1406 ◽

Cited By ~ 208

Author(s):

Peter Hoskin ◽

Oliver Sartor ◽

Joe M O'Sullivan ◽

Dag Clement Johannessen ◽

Svein I Helle ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Subgroup Analysis ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Castration Resistant ◽

Radium 223

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases

International Journal of Clinical Oncology ◽

10.1007/s10147-017-1130-1 ◽

2017 ◽

Vol 22 (5) ◽

pp. 954-963 ◽

Cited By ~ 6

Author(s):

Hiroji Uemura ◽

Hirotsugu Uemura ◽

Nobuaki Matsubara ◽

Seigo Kinuya ◽

Makoto Hosono ◽

...

Keyword(s):

Prostate Cancer ◽

Bone Metastases ◽

Japanese Patients ◽

Safety And Efficacy ◽

Castration Resistant ◽

Radium 223

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study

Yearbook of Urology ◽

10.1016/j.yuro.2011.06.011 ◽

2011 ◽

Vol 2011 ◽

pp. 74-75

Author(s):

A.S. Kibel

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Bone Metastases ◽

Blind Study ◽

Double Blind Study ◽

Double Blind ◽

Castration Resistant